Antiviral agents for dengue virus

Yinghan Jiang; Yanran Wang; Yaqun Xu; Yuxin Tian; Mengyuan Zhao; Chenguang Shen; Yang Yang; Minghui Yang

doi:10.1016/j.virs.2025.11.009

December 2025

Citation: Yinghan Jiang, Yanran Wang, Yaqun Xu, Yuxin Tian, Mengyuan Zhao, Chenguang Shen, Yang Yang, Minghui Yang. Antiviral agents for dengue virus .VIROLOGICA SINICA, 2025, 40(6) : 865-873. http://dx.doi.org/10.1016/j.virs.2025.11.009

Antiviral agents for dengue virus

Yinghan Jiang ^a,b,c ,
Yanran Wang ^d ,
Yaqun Xu ^e ,
Yuxin Tian ^a,b,c ,
Mengyuan Zhao ^a,b,c ,
Chenguang Shen ^{f
,,} ,
Yang Yang ^{g
,,} ,
Minghui Yang ^{a,b,c,e
,,}

a. School of Interdisciplinary Science, Beijing Institute of Technology, Beijing 100081, China;
b. School of Life Science, Beijing Institute of Technology, Beijing 100081, China;
c. Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing 100081, China;
d. Capital Center for Children's Health, Capital Medical University, Beijing 100069, China;
e. Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Zhuhai 519088, China;
f. BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research School of Public Health, Department of Laboratory Medicine, Zhujiang Hospital, Key Laboratory of Infectious Diseases Research in South China, Southern Medical University, Ministry of Education, Guangzhou 510280, China;
g. National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, China

Corresponding author: Chenguang Shen, a124965468@smu.edu.cn
Yang Yang, young@mail.sustech.edu.cn
Minghui Yang, yangmh17@bit.edu.cn
Received Date: 02 July 2025
Accepted Date: 24 November 2025
Available online: 26 November 2025

Abstract

Dengue virus (DENV) is a mosquito-borne pathogen responsible for a spectrum of illnesses, including dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. Nearly half of the global population is at risk of DENV infection, making it a pressing public health issue worldwide. The limited cross-protection among the four DENV serotypes (DENV1-4) and the phenomenon of antibody-dependent enhancement (ADE) have posed significant challenges to the development of effective dengue vaccines. Furthermore, there are currently no specific antiviral treatments available. This review provides an overview of DENV's key characteristics, clinical manifestations, and recent advancements in antiviral drug development—including the repurposing of approved drugs, peptide-based antiviral agents, therapeutic antibodies, natural products with antiviral potential, and host factor inhibitors—aiming to offer critical insights to inform strategies for managing and preventing dengue outbreaks.
- Dengue virus
- , Peptides drugs
- , Antiviral agents
- , Flavivirus

References
1. Alen MM, De Burghgraeve T, Kaptein SJ, Balzarini J, Neyts J, Schols D. 2011. Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One, 6: e21658.
2. Alhoot MA, Rathinam AK, Wang SM, Manikam R, Sekaran SD. 2013. Inhibition of dengue virus entry into target cells using synthetic antiviral peptides. Int J Med Sci, 10: 719-729.
3. Alvin Chew BL, Pan Q, Hu H, Luo D. 2024. Structural biology of flavivirus ns1 protein and its antibody complexes. Antiviral Res, 227: 105915.
4. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe, 8: 271-283.
5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GRW, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature, 496: 504-507.
6. Botta L, Rivara M, Zuliani V, Radi M. 2018. Drug repurposing approaches to fight dengue virus infection and related diseases. Front Biosci (Landmark Ed), 23: 997-1019.
7. Brown JA, Espiritu MV, Abraham J, Thorpe IF. 2016. Computational predictions suggest that structural similarity in viral polymerases may lead to comparable allosteric binding sites. Virus Res, 222: 80-93.
8. Chen JM, Fan YC, Lin JW, Chen YY, Hsu WL, Chiou SS. 2017. Bovine lactoferrin inhibits dengue virus infectivity by interacting with heparan sulfate, low-density lipoprotein receptor, and dc-sign. Int J Mol Sci, 18.
9. Chen YL, Abdul Ghafar N, Karuna R, Fu Y, Lim SP, Schul W, Gu F, Herve M, Yokohama F, Wang G, Cerny D, Fink K, Blasco F, Shi PY. 2014. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. J Virol, 88: 1740-1747.
10. Chew MF, Tham HW, Rajik M, Sharifah SH. 2015. Anti-dengue virus serotype 2 activity and mode of action of a novel peptide. J Appl Microbiol, 119: 1170-1180.
11. Cui G, Si L, Wang Y, Zhou J, Yan H, Jiang L. 2021. Antibody-dependent enhancement (ade) of dengue virus: Identification of the key amino acid that is vital in denv vaccine research. J Gene Med, 23: e3297.
12. Dai L, Xu K, Li J, Huang Q, Song J, Han Y, Zheng T, Gao P, Lu X, Yang H, Liu K, Xia Q, Wang Q, Chai Y, Qi J, Yan J, Gao GF. 2021. Protective zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch. Nat Immunol, 22: 958-968.
13. DeWald LE, Starr C, Butters T, Treston A, Warfield KL. 2020. Iminosugars: A host-targeted approach to combat flaviviridae infections. Antiviral Research, 184: 104881.
14. Diamond MS, Zachariah M, Harris E. 2002. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral rna. Virology, 304: 211-221.
15. Farias KJ, Machado PR, da Fonseca BA. 2013. Chloroquine inhibits dengue virus type 2 replication in vero cells but not in c6/36 cells. ScientificWorldJournal, 2013: 282734.
16. Fibriansah G, Lim EXY, Marzinek JK, Ng TS, Tan JL, Huber RG, Lim XN, Chew VSY, Kostyuchenko VA, Shi J, Anand GS, Bond PJ, Crowe JE, Jr., Lok SM. 2021. Antibody affinity versus dengue morphology influences neutralization. PLoS Pathog, 17: e1009331.
17. Fjell CD, Hiss JA, Hancock RE, Schneider G. 2011. Designing antimicrobial peptides: Form follows function. Nat Rev Drug Discov, 11: 37-51.
18. Fox JL. 2013. Antimicrobial peptides stage a comeback. Nat Biotechnol, 31: 379-382.
19. Frei JC, Wirchnianski AS, Govero J, Vergnolle O, Dowd KA, Pierson TC, Kielian M, Girvin ME, Diamond MS, Lai JR. 2018. Engineered dengue virus domain iii proteins elicit cross-neutralizing antibody responses in mice. J Virol, 92: e01023-18.
20. Haider N, Hasan MN, Onyango J, Billah M, Khan S, Papakonstantinou D, Paudyal P, Asaduzzaman M. 2025. Global dengue epidemic worsens with record 14 million cases and 9000 deaths reported in 2024. International Journal of Infectious Diseases, 158: 107940.
21. Han YS, Penthala NR, Oliveira M, Mesplede T, Xu H, Quan Y, Crooks PA, Wainberg MA. 2017. Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay. J Med Virol, 89: 397-407.
22. Heaton NS, Perera R, Berger KL, Khadka S, Lacount DJ, Kuhn RJ, Randall G. 2010. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci U S A, 107: 17345-17350.
23. Hitakarun A, Khongwichit S, Wikan N, Roytrakul S, Yoksan S, Rajakam S, Davidson AD, Smith DR. 2020. Evaluation of the antiviral activity of orlistat (tetrahydrolipstatin) against dengue virus, japanese encephalitis virus, zika virus and chikungunya virus. Scientific Reports, 10: 1499.
24. Hu D, Zhu Z, Li S, Deng Y, Wu Y, Zhang N, Puri V, Wang C, Zou P, Lei C, Tian X, Wang Y, Zhao Q, Li W, Prabakaran P, Feng Y, Cardosa J, Qin C, Zhou X, Dimitrov DS, Ying T. 2019. A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain iii. PLoS Pathog, 15: e1007836.
25. Huang YN, Lee KY, Shiao SH, Chen CH, Yu GY, Yu MJ. 2024. Bloodmeals fuel dengue virus replication in the female mosquito aedes aegypti. J Virol, 98: e0070124.
26. Injampa S, Muenngern N, Pipattanaboon C, Benjathummarak S, Boonha K, Hananantachai H, Wongwit W, Ramasoota P, Pitaksajjakul P. 2017. Generation and characterization of cross neutralizing human monoclonal antibody against 4 serotypes of dengue virus without enhancing activity. PeerJ, 5: e4021.
27. Jans DA, Wagstaff KM. 2020. Ivermectin as a broad-spectrum host-directed antiviral: The real deal? Cells, 9: 2100.
28. Joubert J, Foxen EB, Malan SF. 2018. Microwave optimized synthesis of n-(adamantan-1-yl)-4-[(adamantan-1-yl)-sulfamoyl]benzamide and its derivatives for anti-dengue virus activity. Molecules, 23, 1678.
29. Kaushik S, Dar L, Kaushik S, Yadav JP. 2021. Identification and characterization of new potent inhibitors of dengue virus ns5 proteinase from andrographis paniculata supercritical extracts on in animal cell culture and in silico approaches. J Ethnopharmacol, 267: 113541.
30. Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman NA. 2006. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, boesenbergia rotunda (l.), towards dengue-2 virus ns3 protease. Bioorg Med Chem Lett, 16: 3337-3340.
31. Koff WC, Elm JL, Halstead SB. 1981. Suppression of dengue virus-replication invitro by rimantadine hydrochloride. American Journal of Tropical Medicine and Hygiene, 30: 184-189.
32. Leardkamolkarn V, Sirigulpanit W, Phurimsak C, Kumkate S, Himakoun L, Sripanidkulchai B. 2012. The inhibitory actions of houttuynia cordata aqueous extract on dengue virus and dengue-infected cells. Journal of Food Biochemistry, 36: 86-92.
33. Li G, De Clercq E. 2017. Current therapy for chronic hepatitis c: The role of direct-acting antivirals. Antiviral Res, 142: 83-122.
34. Li J, Watterson D, Chang CW, Che XY, Li XQ, Ericsson DJ, Qiu LW, Cai JP, Chen J, Fry SR, Cheung STM, Cooper MA, Young PR, Kobe B. 2018. Structural and functional characterization of a cross-reactive dengue virus neutralizing antibody that recognizes a cryptic epitope. Structure, 26: 51-59.e54.
35. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. 2008. The flavivirus precursor membrane-envelope protein complex: Structure and maturation. Science, 319: 1830-1834.
36. Liao YC, Yeh CC, Chueh YF, Huang MS, Wu JS, Wen YX, Chang YT, Lai YR, Chen JJ, Chang TH. 2024. Effects of the oxoaporphine alkaloid hernandonine on dengue virus. Evidence for its mechanisms of action. Phytomedicine, 134: 155986.
37. Lin CC, Chen WC. 2016. Treatment effectiveness of amantadine against dengue virus infection. Am J Case Rep, 17: 921-924.
38. Lin KH, Ali A, Rusere L, Soumana DI, Kurt Yilmaz N, Schiffer CA. 2017. Dengue virus ns2b/ns3 protease inhibitors exploiting the prime side. J Virol, 91: e00045-17.
39. Liu X, Li Z, Li X, Wu W, Jiang H, Zheng Y, Zhou J, Ye X, Lu J, Wang W, Yu L, Li Y, Qu L, Wang J, Li F, Chen L, Wu L, Feng L. 2024. A single-dose circular rna vaccine prevents zika virus infection without enhancing dengue severity in mice. Nat Commun, 15: 8932.
40. Lok S-M, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nature Structural & Molecular Biology, 15: 312-317.
41. Masrinoul P, Omokoko MD, Pambudi S, Ikuta K, Kurosu T. 2013. Serotype-specific anti-dengue virus ns1 mouse antibodies cross-react with prm and are potentially involved in virus production. Viral Immunol, 26: 250-258.
42. Mateo R, Nagamine CM, Kirkegaard K. 2015. Suppression of drug resistance in dengue virus. mBio, 6: e01960-01915.
43. Murugan K, Panneerselvam C, Subramaniam J, Paulpandi M, Rajaganesh R, Vasanthakumaran M, Madhavan J, Shafi SS, Roni M, Portilla-Pulido JS, Mendez SC, Duque JE, Wang L, Aziz AT, Chandramohan B, Dinesh D, Piramanayagam S, Hwang JS. 2022. Synthesis of new series of quinoline derivatives with insecticidal effects on larval vectors of malaria and dengue diseases. Sci Rep, 12: 4765.
44. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh Hle A, Farrar J, Nguyen QT, Tran HT, Nguyen CV, Merson L, Hoang LT, Hibberd ML, Aw PP, Wilm A, Nagarajan N, Nguyen DT, Pham MP, Nguyen TT, Javanbakht H, Klumpp K, Hammond J, Petric R, Wolbers M, Nguyen CT, Simmons CP. 2013. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis, 207: 1442-1450.
45. Nncube NB, Ramharack P, Soliman MES. 2018. Using bioinformatics tools for the discovery of dengue rna-dependent rna polymerase inhibitors. PeerJ, 6: e5068.
46. Paemanee A, Hitakarun A, Wintachai P, Roytrakul S, Smith DR. 2019. A proteomic analysis of the anti-dengue virus activity of andrographolide. Biomed Pharmacother, 109: 322-332.
47. Panwong S, Phinyo K, Duangjan K, Sattayawat P, Pekkoh J, Tragoolpua Y, Yenchitsomanus PT, Panya A. 2024. Inhibition of dengue virus infection in vitro by fucoidan and polysaccharide extract from marine alga sargassum spp. Int J Biol Macromol, 276: 133496.
48. Panya A, Bangphoomi K, Choowongkomon K, Yenchitsomanus PT. 2014. Peptide inhibitors against dengue virus infection. Chem Biol Drug Des, 84: 148-157.
49. Panya A, Sawasdee N, Junking M, Srisawat C, Choowongkomon K, Yenchitsomanus PT. 2015. A peptide inhibitor derived from the conserved ectodomain region of denv membrane (m) protein with activity against dengue virus infection. Chem Biol Drug Des, 86: 1093-1104.
50. Panya A, Songprakhon P, Panwong S, Jantakee K, Kaewkod T, Tragoolpua Y, Sawasdee N, Lee VS, Nimmanpipug P, Yenchitsomanus PT. 2021. Cordycepin inhibits virus replication in dengue virus-infected vero cells. Molecules, 26: 3118.
51. Pastorino B, Nougairede A, Wurtz N, Gould E, de Lamballerie X. 2010. Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs. Antiviral Res, 87: 281-294.
52. Prompetchara E, Ketloy C, Thomas SJ, Ruxrungtham K. 2020. Dengue vaccine: Global development update. Asian Pac J Allergy Immunol, 38: 178-185.
53. Rafi S, Yasmin S, Uddin R. 2022. A molecular dynamic simulation approach: Development of dengue virus vaccine by affinity improvement techniques. J Biomol Struct Dyn, 40: 61-76.
54. Ratanakomol T, Roytrakul S, Wikan N, Smith DR. 2021. Berberine inhibits dengue virus through dual mechanisms. Molecules, 26: 5501.
55. Recalde-Reyes DP, Rodriguez-Salazar CA, Castano-Osorio JC, Giraldo MI. 2022. Pd1 cd44 antiviral peptide as an inhibitor of the protein-protein interaction in dengue virus invasion. Peptides, 153: 170797.
56. Richard AS, Zhang A, Park SJ, Farzan M, Zong M, Choe H. 2015. Virion-associated phosphatidylethanolamine promotes tim1-mediated infection by ebola, dengue, and west nile viruses. Proc Natl Acad Sci U S A, 112: 14682-14687.
57. Rodenhuis-Zybert IA, Wilschut J, Smit JM. 2010. Dengue virus life cycle: Viral and host factors modulating infectivity. Cell Mol Life Sci, 67: 2773-2786.
58. Rodenhuis-Zybert IA, Moesker B, da Silva Voorham JM, van der Ende-Metselaar H, Diamond MS, Wilschut J, Smit JM. 2011. A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J Virol, 85: 11800-11808.
59. Samsa MM, Mondotte JA, Iglesias NG, Assuncao-Miranda I, Barbosa-Lima G, Da Poian AT, Bozza PT, Gamarnik AV. 2009. Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathog, 5: e1000632.
60. Sarker A, Dhama N, Gupta RD. 2023. Dengue virus neutralizing antibody: A review of targets, cross-reactivity, and antibody-dependent enhancement. Front Immunol, 14: 1200195.
61. Schmidt AG, Yang PL, Harrison SC. 2010. Peptide inhibitors of flavivirus entry derived from the e protein stem. J Virol, 84: 12549-12554.
62. Schwickert KK, Glitscher M, Bender D, Benz NI, Murra R, Schwickert K, Pfalzgraf S, Schirmeister T, Hellmich UA, Hildt E. 2024. Zika virus replication is impaired by a selective agonist of the trpml2 ion channel. Antiviral Res, 228: 105940.
63. Shi X, Deng Y, Wang H, Ji G, Tan W, Jiang T, Li X, Zhao H, Xia T, Meng Y, Wang C, Yu X, Yang Y, Li B, Qin ED, Dai J, Qin CF, Guo Y. 2016. A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion. MAbs, 8: 574-584.
64. Shukla R, Ahuja R, Beesetti H, Garg A, Aggarwal C, Chaturvedi S, Nayyar K, Arora U, Lal AA, Khanna N. 2023. Sinococuline, a bioactive compound of cocculus hirsutus has potent anti-dengue activity. Sci Rep, 13: 1026.
65. Simanjuntak Y, Liang JJ, Lee YL, Lin YL. 2015. Repurposing of prochlorperazine for use against dengue virus infection. J Infect Dis, 211: 394-404.
66. Sreekanth GP. 2023. Perspectives on the current antiviral developments towards rna-dependent rna polymerase (rdrp) and methyltransferase (mtase) domains of dengue virus non-structural protein 5 (denv-ns5). Eur J Med Chem, 256: 115416.
67. Talarico LB, Pujol CA, Zibetti RGM, Faria PCS, Noseda MD, Duarte MER, Damonte EB. 2005. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Research, 66: 103-110.
68. Tan BEK, Tham SK, Poh CL. 2025. Development of new live-attenuated vaccine candidates lacking antibody-dependent enhancement (ade) against dengue. Vaccines (Basel), 13: 532.
69. Tian YS, Zhou Y, Takagi T, Kameoka M, Kawashita N. 2018. Dengue virus and its inhibitors: A brief review. Chem Pharm Bull (Tokyo), 66: 191-206.
70. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, Tran HT, Simmons CP. 2010. A randomized controlled trial of chloroquine for the treatment of dengue in vietnamese adults. PLoS Negl Trop Dis, 4: e785.
71. Uhlig T, Kyprianou T, Martinelli FG, Oppici CA, Heiligers D, Hills D, Calvo XR, Verhaert P. 2014. The emergence of peptides in the pharmaceutical business: From exploration to exploitation. EuPA Open Proteomics, 4: 58-69.
72. Varga N, Sutkeviciute I, Ribeiro-Viana R, Berzi A, Ramdasi R, Daghetti A, Vettoretti G, Amara A, Clerici M, Rojo J, Fieschi F, Bernardi A. 2014. A multivalent inhibitor of the dc-sign dependent uptake of hiv-1 and dengue virus. Biomaterials, 35: 4175-4184.
73. Wahala WM, Silva AM. 2011. The human antibody response to dengue virus infection. Viruses, 3: 2374-2395.
74. Wei H, Tan J, Zhou B, Guan X, Zhong Q, Wang J. 2022. Charged residue implantation improves the affinity of a cross-reactive dengue virus antibody. Int J Mol Sci, 23: 4197.
75. Whitehorn J, Nguyen CVV, Khanh LP, Kien DTH, Quyen NTH, Tran NTT, Hang NT, Truong NT, Hue Tai LT, Cam Huong NT, Nhon VT, Van Tram T, Farrar J, Wolbers M, Simmons CP, Wills B. 2016. Lovastatin for the treatment of adult patients with dengue: A randomized, double-blind, placebo-controlled trial. Clin Infect Dis, 62: 468-476.
76. Williams KL, Sukupolvi-Petty S, Beltramello M, Johnson S, Sallusto F, Lanzavecchia A, Diamond MS, Harris E. 2013. Therapeutic efficacy of antibodies lacking fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog, 9: e1003157.
77. Wilson ME, Chen LH. 2015. Dengue: Update on epidemiology. Curr Infect Dis Rep, 17: 457.
78. Xu HT, Colby-Germinario SP, Hassounah SA, Fogarty C, Osman N, Palanisamy N, Han Y, Oliveira M, Quan Y, Wainberg MA. 2017a. Evaluation of sofosbuvir (β-d-2'-deoxy-2'-α-fluoro-2'-β-c-methyluridine) as an inhibitor of dengue virus replication<sup/>. Sci Rep, 7: 6345.
79. Xu M, Zuest R, Velumani S, Tukijan F, Toh YX, Appanna R, Tan EY, Cerny D, MacAry P, Wang C-I, Fink K. 2017b. A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus. npj Vaccines, 2: 2.
80. Yang M, Wei J, Huang T, Lei L, Shen C, Lai J, Yang M, Liu L, Yang Y, Liu G, Liu Y. 2021. Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in cultured vero cells. Phytother Res, 35: 1127-1129.
81. Yao X, Ling Y, Guo S, He S, Wang J, Zhang Q, Wu W, Zou M, Zhang T, Nandakumar KS, Chen X, Liu S. 2018. Inhibition of dengue viral infection by diasarone-i is associated with 2'o methyltransferase of ns5. Eur J Pharmacol, 821: 11-20.
82. Yauch LE, Shresta S. 2014. Dengue virus vaccine development. Adv Virus Res, 88: 315-372.
83. Ye G, Tang Y, Yang Q, Zhang C, Shi H, Wang J, Hu X, Wan X, Xu Z, Liang J, Yang Y, Yang M, Liu Y. 2024. A peptide derived from sars-cov-2 nucleocapsid protein with broad-spectrum anti-coronavirus activity. J Med Virol, 96: e29492.
84. Yeo KL, Chen YL, Xu HY, Dong H, Wang QY, Yokokawa F, Shi PY. 2015. Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors. Antimicrob Agents Chemother, 59: 2086-2093.
85. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A, 106: 20435-20439.
86. Zhu, X., Gao, X., Wu, Y., Lu, J., Chen, X., Zhao, C., Li, H., Zhang, Z., Liu, S., Xiao, G., & Pan, X. (2025). Eltrombopag, an FDA-approved drug, inhibits dengue virus type 2 by targeting NS2B-NS3 protease. Virologica Sinica, 40, 439-450.
Proportional views